Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI).
COVID-19
antibodies
long-term care facilities
vaccination
waning
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
28 11 2022
28 11 2022
Historique:
received:
01
02
2022
accepted:
14
04
2022
pubmed:
17
4
2022
medline:
1
12
2022
entrez:
16
4
2022
Statut:
ppublish
Résumé
General population studies have shown strong humoral response following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination with subsequent waning of anti-spike antibody levels. Vaccine-induced immune responses are often attenuated in frail and older populations, but published data are scarce. We measured SARS-CoV-2 anti-spike antibody levels in long-term care facility residents and staff following a second vaccination dose with Oxford-AstraZeneca or Pfizer-BioNTech. Vaccination elicited robust antibody responses in older residents, suggesting comparable levels of vaccine-induced immunity to that in the general population. Antibody levels are higher after Pfizer-BioNTech vaccination but fall more rapidly compared to Oxford-AstraZeneca recipients and are enhanced by prior infection in both groups.
Identifiants
pubmed: 35429382
pii: 6569361
doi: 10.1093/infdis/jiac146
pmc: PMC9047242
doi:
Substances chimiques
ChAdOx1 nCoV-19
B5S3K2V0G8
BNT162 Vaccine
0
Vaccines
0
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1877-1881Subventions
Organisme : Wellcome Trust
ID : 222907/Z/21/Z
Pays : United Kingdom
Organisme : Department of Health
ID : CS-2016-007
Pays : United Kingdom
Organisme : Medical Research Council
Pays : United Kingdom
Organisme : Chief Scientist Office
Pays : United Kingdom
Organisme : British Heart Foundation
Pays : United Kingdom
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. L. S., T. P., A. C., and O. S. report grants from the Department of Health and Social Care during the conduct of the study, and L. S. is a member of the Social Care Working Group, which reports to the Scientific Advisory Group for Emergencies. A. I.-S. and V. B. are employed by the Department of Health and Social Care, which funded the study. A. H. reports funding from the Covid Core Studies Programme and is a member of the New and Emerging Respiratory Virus Threats Advisory Group at the Department of Health and Environmental Modelling Group of the Scientific Advisory Group for Emergencies. All other authors report no potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
Clin Microbiol Infect. 2021 Oct;27(10):1516.e7-1516.e14
pubmed: 34111577
Lancet Healthy Longev. 2021 Sep;2(9):e544-e553
pubmed: 34430954
Lancet Infect Dis. 2020 Dec;20(12):1390-1400
pubmed: 32979318
Wellcome Open Res. 2020 Oct 7;5:232
pubmed: 33564722
Nat Med. 2022 May;28(5):1072-1082
pubmed: 35165453
Lancet Healthy Longev. 2022 Jan;3(1):e13-e21
pubmed: 34935001
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Front Aging. 2021 Mar 17;2:599084
pubmed: 35821989
Lancet Healthy Longev. 2021 Sep;2(9):e554-e560
pubmed: 34401865